{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:53Z","timestamp":1791413333078,"version":"4.3.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 AI-065357"],"award-info":[{"award-number":["U54 AI-065357"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201000039I"],"award-info":[{"award-number":["HHSN272201000039I"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.antiviral.2015.12.006","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T18:45:22Z","timestamp":1450550722000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses"],"prefix":"10.1016","volume":"126","author":[{"given":"Jonna B.","family":"Westover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sefing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud J.","family":"Van Wettere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Dagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luci","family":"Wandersee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Smee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.12.006_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.12.006_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2015.12.006_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965359900400404","article-title":"Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group","volume":"4","author":"Chapman","year":"1999","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2015.12.006_bib4","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.12.006_bib5","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/JVI.02102-10","article-title":"Rescue from cloned cDNAs and in\u00a0vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease","volume":"85","author":"Emonet","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2015.12.006_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0166-3542(94)90030-2","article-title":"Antiviral treatment of Argentine hemorrhagic fever","volume":"23","author":"Enria","year":"1994","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.006_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.006_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.006_bib9","doi-asserted-by":"crossref","first-page":"e2614","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.12.006_bib10","doi-asserted-by":"crossref","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","article-title":"Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin","volume":"3","author":"Gowen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2015.12.006_bib11","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In\u00a0vitro and in\u00a0vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.006_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.12.006_bib13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/j.gastro.2010.12.038","article-title":"Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function","volume":"140","author":"Hitomi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.12.006_bib14","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.01579-07","article-title":"Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice","volume":"52","author":"Ilyushina","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.006_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0041-008X(80)90252-5","article-title":"Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice","volume":"52","author":"Kochhar","year":"1980","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.antiviral.2015.12.006_bib16","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.12.006_bib17","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.12.006_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A\u00a0three-dimensional model to analyze drug\u2013drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.006_bib19","first-page":"493","article-title":"A\u00a0simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2015.12.006_bib20","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.12.006_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2015.12.006_bib22","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1473-3099(15)00229-7","article-title":"Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report","volume":"15","author":"Schibler","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.12.006_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215300450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T23:33:05Z","timestamp":1653867185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215300450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":23,"alternative-id":["S0166354215300450"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}